Inogen’s (INGN) Hold Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Inogen (NASDAQ:INGN) in a research note released on Tuesday morning,Benzinga reports.

Separately, StockNews.com cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

Inogen Trading Down 3.3 %

NASDAQ INGN opened at $10.52 on Tuesday. Inogen has a 12 month low of $5.08 and a 12 month high of $13.33. The stock has a 50 day moving average of $9.54 and a 200-day moving average of $9.91. The company has a market cap of $250.59 million, a PE ratio of -4.68 and a beta of 1.02.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Quarry LP bought a new position in Inogen during the third quarter worth $59,000. Verition Fund Management LLC acquired a new stake in shares of Inogen during the 3rd quarter worth about $106,000. Virtu Financial LLC bought a new stake in shares of Inogen during the 3rd quarter worth about $111,000. Paloma Partners Management Co acquired a new position in Inogen in the 3rd quarter valued at about $126,000. Finally, Centiva Capital LP bought a new position in Inogen in the 3rd quarter valued at about $138,000. 89.94% of the stock is owned by institutional investors and hedge funds.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.